TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET 84
1.4 LIMITATIONS 86
1.5 MARKETS COVERED 87
2 MARKET SEGMENTATION 90
2.1 MARKETS COVERED 90
2.2 GEOGRAPHICAL SCOPE 91
2.3 YEARS CONSIDERED FOR THE STUDY 92
2.4 CURRENCY AND PRICING 92
2.5 DBMR TRIPOD DATA VALIDATION MODEL 93
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE LIFELINE CURVE 96
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.9 DBMR MARKET POSITION GRID 98
2.10 MARKET APPLICATION COVERAGE GRID 99
2.11 VENDOR SHARE ANALYSIS 100
2.12 SECONDARY SOURCES 101
2.13 ASSUMPTIONS 101
3 EXECUTIVE SUMMARY 102
4 PREMIUM INSIGHTS 106
4.1 PESTEL ANALYSIS 108
4.2 PORTER'S 5 FORCES 109
5 INDUSTRY INSIGHTS 110
6 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, REGULATIONS 111
7 MARKET OVERVIEW 113
7.1 DRIVERS 115
7.1.1 INCREASED GROWTH IN PREVALENCE OF NON-HODGKIN LYMPHOMA 115
7.1.2 INCREASE IN AWARENESS REGARDING NON-HODGKIN LYMPHOMA 115
7.1.3 ADVANCEMENT IN ARTIFICIAL INTELLIGENCE IN DIAGNOSIS OF NON-HODGKIN LYMPHOMA 115
7.1.4 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UP 116
7.2 RESTRAINTS 116
7.2.1 LACK OF AVAILABILITY OF TRAINED AND SKILLED MEDICAL PROFESSIONALS 116
7.2.2 STRINGENT REGULATIONS AND GUIDELINES FOR DIFFERENT TREATMENTS AND DIAGNOSIS 117
7.3 OPPORTUNITIES 118
7.3.1 TECHNICAL ADVANCEMENTS IN CANCER DIAGNOSIS 118
7.3.2 INCREASING HEALTHCARE EXPENDITURE IN CANCER R&D 118
7.3.3 GROWING INITIATIVES BY GOVERNMENT AND KEY PLAYERS 118
7.4 CHALLENGES 119
7.4.1 LACK OF EARLY DIAGNOSTIC AWARENESS AMONG PEOPLE 119
7.4.2 HIGH DIAGNOSTIC COST AND FEAR OF TREATMENT 119
7.4.3 COMMON MISDIAGNOSIS OF NON-HODGKIN LYMPHOMA (NHL) 120
8 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TEST TYPE 121
8.1 OVERVIEW 122
8.2 IMAGING 125
8.2.1 COMPUTED TOMOGRAPHY (CT) 126
8.2.2 CHEST X-RAY 126
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 126
8.2.4 ULTRASOUND 126
8.2.5 POSITRON EMISSION TOMOGRAPHY (PET) 126
8.3 BIOPSY 126
8.3.1 EXCISIONAL OR INCISIONAL BIOPSY 127
8.3.2 CORE NEEDLE BIOPSY 127
8.4 IMMUNOHISTOCHEMISTRY 127
8.5 BIOMARKER TEST 128
8.5.1 BETA 2-M 129
8.5.2 LDH 129
8.5.3 CA-125 129
8.5.4 TP53 129
8.5.5 NPM1 130
8.5.6 OTHERS 130
8.6 GENETIC TEST 130
8.7 CYTOGENETICS 130
8.8 LUMBAR PUNCTURE (SPINAL TAP) 131
8.9 BLOOD TEST 132
8.10 CYTOCHEMISTRY 132
8.11 OTHERS 133
9 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TUMOR TYPE 134
9.1 OVERVIEW 135
9.2 AGGRESSIVE LYMPHOMAS 137
9.2.1 DIFFUSE LARGE B CELL LYMPHOMA 138
9.2.1.1 INSTRUMENT BASED PRODUCTS 139
9.2.1.2 PLATFORM BASED PRODUCTS 139
9.2.1.3 KITS AND REAGENTS 139
9.2.1.4 OTHER CONSUMABLES 139
9.2.2 ANAPLASTIC LARGE-CELL LYMPHOMA 139
9.2.2.1 INSTRUMENT BASED PRODUCTS 140
9.2.2.2 PLATFORM BASED PRODUCTS 140
9.2.2.3 KITS AND REAGENTS 140
9.2.2.4 OTHER CONSUMABLES 140
9.2.3 MANTLE CELL LYMPHOMA 140
9.2.3.1 INSTRUMENT BASED PRODUCTS 141
9.2.3.2 PLATFORM BASED PRODUCTS 141
9.2.3.3 KITS AND REAGENTS 141
9.2.3.4 OTHER CONSUMABLES 141
9.2.4 PERIPHERAL T-CELL LYMPHOMA 141
9.2.4.1 INSTRUMENT BASED PRODUCTS 142
9.2.4.2 PLATFORM BASED PRODUCTS 142
9.2.4.3 KITS AND REAGENTS 142
9.2.4.4 OTHER CONSUMABLES 142
9.2.5 LYMPHOBLASTIC LYMPHOMA 142
9.2.5.1 INSTRUMENT BASED PRODUCTS 143
9.2.5.2 PLATFORM BASED PRODUCTS 143
9.2.5.3 KITS AND REAGENTS 143
9.2.5.4 OTHER CONSUMABLES 143
9.2.6 BURKITT LYMPHOMA 143
9.2.6.1 INSTRUMENT BASED PRODUCTS 144
9.2.6.2 PLATFORM BASED PRODUCTS 144
9.2.6.3 KITS AND REAGENTS 144
9.2.6.4 OTHER CONSUMABLES 144
9.3 INDOLENT LYMPHOMAS 144
9.3.1 FOLLICULAR LYMPHOMA 145
9.3.1.1 INSTRUMENT BASED PRODUCTS 146
9.3.1.2 PLATFORM BASED PRODUCTS 146
9.3.1.3 KITS AND REAGENTS 146
9.3.1.4 OTHER CONSUMABLES 146
9.3.2 CUTANEOUS T-CELL LYMPHOMA 146
9.3.2.1 INSTRUMENT BASED PRODUCTS 147
9.3.2.2 PLATFORM BASED PRODUCTS 147
9.3.2.3 KITS AND REAGENTS 147
9.3.2.4 OTHER CONSUMABLES 147
9.3.3 MARGINAL ZONE B CELL LYMPHOMA 147
9.3.3.1 INSTRUMENT BASED PRODUCTS 148
9.3.3.2 PLATFORM BASED PRODUCTS 148
9.3.3.3 KITS AND REAGENTS 148
9.3.3.4 OTHER CONSUMABLES 148
9.3.4 LYMPHOPLASMACYTIC LYMPHOMA 148
9.3.4.1 INSTRUMENT BASED PRODUCTS 149
9.3.4.2 PLATFORM BASED PRODUCTS 149
9.3.4.3 KITS AND REAGENTS 149
9.3.4.4 OTHER CONSUMABLES 149
9.3.5 SMALL-CELL LYMPHOCYTIC LYMPHOMA 149
9.3.5.1 INSTRUMENT BASED PRODUCTS 150
9.3.5.2 PLATFORM BASED PRODUCTS 150
9.3.5.3 KITS AND REAGENTS 150
9.3.5.4 OTHER CONSUMABLES 150
10 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY APPLICATION 151
10.1 OVERVIEW 152
10.2 SCREENING 154
10.2.1 INSTRUMENT BASED PRODUCTS 155
10.2.2 PLATFORM BASED PRODUCTS 155
10.2.3 KITS AND REAGENTS 156
10.2.4 OTHER CONSUMABLES 156
10.3 DIAGNOSTIC AND PREDICTIVE 156
10.3.1 INSTRUMENT BASED PRODUCTS 157
10.3.2 PLATFORM BASED PRODUCTS 157
10.3.3 KITS AND REAGENTS 157
10.3.4 OTHER CONSUMABLES 157
10.4 PROGNOSTIC 157
10.4.1 INSTRUMENT BASED PRODUCTS 158
10.4.2 PLATFORM BASED PRODUCTS 158
10.4.3 KITS AND REAGENTS 158
10.4.4 OTHER CONSUMABLES 159
10.5 RESEARCH 159
10.5.1 INSTRUMENT BASED PRODUCTS 160
10.5.2 PLATFORM BASED PRODUCTS 160
10.5.3 KITS AND REAGENTS 160
10.5.4 OTHER CONSUMABLES 160
11 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY CANCER STAGE 161
11.1 OVERVIEW 162
11.2 STAGE IV 164
11.3 STAGE I 165
11.4 STAGE III 166
11.5 STAGE II 167
11.6 STAGE 0 168
12 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY TECHNOLOGY 169
12.1 OVERVIEW 170
12.2 FLUORESCENT IN SITU HYBRIDIZATION 172
12.3 NEXT GENERATION SEQUENCING 173
12.4 FLUORIMMUNOASSAY 174
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 175
12.6 IMMUNOHISTOLOCHEMICAL 175
12.7 OTHER 176
13 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY PRODUCT 177
13.1 OVERVIEW 178
13.2 INSTRUMENT BASED PRODUCTS 180
13.2.1 IMAGING 181
13.2.2 BIOPSY 181
13.3 PLATFORM BASED PRODUCTS 182
13.3.1 NEXT-GENERATION SEQUENCING 183
13.3.2 MICROARRAYS 183
13.3.3 PCR 183
13.3.4 OTHERS 183
13.4 KITS AND REAGENTS 183
13.4.1 NON-HODGKIN LYMPHOMA PANELS 184
13.4.2 IMMUNOHISTOCHEMISTRY STAINS 184
13.4.3 OTHERS 184
13.5 OTHER CONSUMABLES 185
14 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY END USER 186
14.1 OVERVIEW 187
14.2 HOSPITALS 189
14.3 DIAGNOSTIC CENTERS 190
14.4 CANCER RESEARCH CENTERS 191
14.5 ACADEMIC INSTITUTES 192
14.6 AMBULATORY SURGICAL CENTERS 192
14.7 OTHERS 193
15 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 194
15.1 OVERVIEW 195
15.2 DIRECT TENDER 197
15.3 RETAIL SALES 198
15.4 OTHERS 199
16 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET, BY REGION 200
16.1 OVERVIEW 201
16.2 NORTH AMERICA 207
16.2.1 U.S. 225
16.2.2 CANADA 237
16.2.3 MEXICO 249
16.3 EUROPE 261
16.3.1 GERMANY 280
16.3.2 UNITED KINGDOM 292
16.3.3 FRANCE 304
16.3.4 ITALY 316
16.3.5 SPAIN 328
16.3.6 RUSSIA 340
16.3.7 NETHERLANDS 352
16.3.8 SWITZERLAND 364
16.3.9 BELGIUM 376
16.3.10 TURKEY 388
16.3.11 REST OF EUROPE 400
16.4 ASIA-PACIFIC 401
16.4.1 CHINA 421
16.4.2 JAPAN 435
16.4.3 INDIA 449
16.4.4 AUSTRALIA 463
16.4.5 SOUTH KOREA 477
16.4.6 INDONESIA 491
16.4.7 PHILIPPINES 505
16.4.8 THAILAND 519
16.4.9 MALAYSIA 533
16.4.10 VIETNAM 547
16.4.11 SINGAPORE 560
16.4.12 REST OF ASIA-PACIFIC 574
16.5 MIDDLE EAST AND AFRICA 575
16.5.1 SOUTH AFRICA 593
16.5.2 SAUDI ARABIA 606
16.5.3 U.A.E. 619
16.5.4 EGYPT 632
16.5.5 ISRAEL 646
16.5.6 REST OF MIDDLE EAST AND AFRICA 660
16.6 SOUTH AMERICA 661
16.6.1 BRAZIL 680
16.6.2 ARGENTINA 694
16.6.3 REST OF SOUTH AMERICA 707
17 GLOBAL NON-HODGKIN LYMPHOMA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 708
17.1 COMPANY SHARE ANALYSIS: GLOBAL 708
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 709
17.3 COMPANY SHARE ANALYSIS: EUROPE 710
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 711
18 SWOT ANALYSIS 712
19 GLOBAL NON-HODKIN LYMPHOMA DIAGNOSTICS MARKET 713
19.1 CANON MEDICAL SYSTEMS CORPORATION 713
19.1.1 COMPANY SNAPSHOT 713
19.1.2 REVENUE ANALYSIS 713
19.1.3 COMPANY SHARE ANALYSIS 714
19.1.4 PRODUCT PORTFOLIO 714
19.1.5 RECENT DEVELOPMENT 714

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.